As shown in Fig. 4a, there was no significant change in the expression levels of RIP1 mRNA between Mel-CV.S and Mel-RMu.S and their corresponding parental counterparts, nor was there any difference in RIP1 mRNA expression levels between fresh melanoma isolates from patients before and after treatment with vemurafenib (Fig. 4b), suggesting that upregulation of RIP1 in melanoma cells with acquired resistance was due to posttranscriptional regulation. The gene discussed is RIPK1; the disease is melanoma.